Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 01 Mar 2018 Status changed from recruiting to discontinued due to changes in treatment plans affecting drug therapy choices.
- 10 Jun 2017 Biomarkers information updated
- 16 Feb 2017 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.